PF-06445974

• Product Name Alternative:

  Mitoglitazone; CAY10415

• UNSPSC Description:

  PF-06445974, a promising positron emission tomography (PET) lead, has exquisite potency at PDE4B with an IC50 50 values are 36, 4.7 and 17 nM for PDE4D, PDE4A and PDE4C, respectively. PF-06445974 has good selectivity over PDE4D, excellent brain permeability, and a high level of specific binding in the "cold tracer" study[1].

• Target Antigen:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pf-06445974.html

• Purity:

  98.23

• Solubility:

  DMSO : 33.33 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  N#CC1=CC=C(C=C1F)C2=C(C3=O)N(CCN3C4CC4)C5=CC=CN=C25

• Molecular Weight:

  346.36

• References & Citations:

  [1]Lei Zhang, et al. The Discovery of a Novel Phosphodiesterase (PDE) 4B-Preferring Radioligand for Positron Emission Tomography (PET) Imaging. J Med Chem. 2017 Oct 26;60(20):8538-8551.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2055776-17-3